TScan Therapeutics

tscan.com →

-71%

est. 2Y upside i

HealthcareSeries C

Rank

#3908

Sector

Biotechnology

Est. Liquidity

~3Y

Data Quality

Data: High

TScan Therapeutics presents a high-risk, moderate-reward equity opportunity for a job seeker.

Last updated: March 10, 2026

Bull (20%)+150%

TScan successfully launches its pivotal TSC-101 trial in Q2 2026 and reports compelling positive data, along with strong initial Phase 1 data for TSC-102 candidates, leading to a significant market re-rating and potential acquisition interest. This could drive the market capitalization to approximately $159M, reflecting a substantial premium for clinical success and pipeline validation.

Base (35%)+20%

TScan makes steady progress in its hematologic malignancy programs, meeting some clinical milestones but facing typical biotech development delays or mixed results. The company maintains its cash runway into H2 2027, but further financing is anticipated. The market capitalization sees a modest increase to around $76M as the company continues its clinical journey.

Bear (45%)-80%

TScan experiences setbacks in its pivotal TSC-101 trial or TSC-102 Phase 1 studies, or faces significant regulatory delays. Coupled with continued high cash burn and the severe liquidation preference of $190M, the company is forced into a highly dilutive financing round or faces severe financial distress. This could lead to a market capitalization of approximately $13M, effectively wiping out most common stock value.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

67%

Investors have contributed $190M in total funding, which significantly exceeds the current market capitalization of approximately $63.7M, indicating that liquidation preferences would absorb the entire company value in an exit at or below the current valuation.

Dilution Risk

high

The company's high cash burn and unprofitability suggest a strong likelihood of needing to raise additional capital in the future, which would lead to further dilution for existing shareholders.

Secondary Liquidity

active

TScan Therapeutics is a publicly traded company on NASDAQ (TCRX), providing active secondary market liquidity for its shares.

Questions to Ask at the Interview

Strategic questions based on TScan Therapeutics's data — designed to show you've done your homework.

  • 1

    “Given the strategic shift to prioritize hematologic malignancies and the discontinuation of the PLEXI-T™ solid tumor trial, how is TScan ensuring its pipeline remains robust and diversified beyond the current lead candidates?”

  • 2

    “With a cash runway extended into H2 2027 and a net loss of $129.8M in FY2025, what are the company's specific plans for future financing, and how will potential dilution for common shareholders be managed?”

  • 3

    “Considering the significant difference between the total funding raised ($190M) and the current market capitalization (~$63.7M), what is the company's perspective on creating value for common stock holders, especially in potential exit scenarios?”

Community

Valuation Sentiment

Our model estimates -71% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.